| Literature DB >> 19679351 |
Jean-Marie Bruey1, Hagop Kantarjian, Zeev Estrov, Zhong Zhang, Wanlong Ma, Ferras Albitar, Adam Abdool, Deborah Thomas, Chenhsiung Yeh, Susan O'Brien, Maher Albitar.
Abstract
Tissue-based determination of Ki-67, a marker of cellular proliferation, has shown prognostic value in solid tumors and hematological malignancies. We developed and validated an electrochemiluminescence-based method for sensitive measurement of circulating Ki-67 in plasma (cKi-67). This assay demonstrated significantly higher levels of cKi-67 in patients with newly diagnosed acute lymphoblastic leukemia (ALL) (n=27; median, 762; range, 0-4574U/100 microL) than in healthy control subjects (n=114; median, 399; range, 36-2830U/100 microL). Moreover, elevated plasma cKi-67 was associated with significantly shorter survival in ALL patients (P=0.05). These findings suggest that Ki-67 can be detected in circulation and has potential for use as a biomarker for predicting clinical behavior in ALL. Copyright 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19679351 PMCID： PMC4132892 DOI： 10.1016/j.leukres.2009.07.030
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156